Full metadata record
DC FieldValueLanguage
dc.creatorTwigg, S.M. (Stephen M.)-
dc.creatorEscalada, J. (Javier)-
dc.creatorStella, P. (Peter)-
dc.creatorMerino-Trigo, A. (A.)-
dc.creatorLavalle-Gonzalez, F.J. (Fernando J.)-
dc.creatorCariou, B. (Bertrand)-
dc.creatorMeneghini, L.F. (Luigi F.)-
dc.identifier.citationTwigg, S.M. (Stephen M.); Escalada, J. (Javier); Stella, P. (Peter); et al. "Association of patient profile with glycemic control and hypoglycemia with insulin glargine 300 U/mL in type 2 diabetes: A post hoc patient-level meta-analysis". Diabetes therapy. 9 (5), 2018, 2043 - 2053es
dc.description.abstractAims To examine the association of baseline patient characteristics with study outcomes in people with type 2 diabetes receiving insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100), over a 6-month period. Methods A post hoc patient-level meta-analysis using data from three multicenter, randomized, open-label, parallel-group, phase 3a studies of similar design, in people previously receiving either basal and prandial insulin, basal insulin + oral antihyperglycemic drugs, or no prior insulin (EDITION 1, 2 and 3, respectively). The endpoints, glycated hemoglobin (HbA1c), hypoglycemia, body weight change, and insulin dose were investigated by subgroups: age (< 65 and ≥ 65 years), body mass index (BMI; < 30 and ≥ 30 kg/m2), age at onset (< 40, 40–50, and > 50 years), and diabetes duration (< 10 and ≥ 10 years). Results Reduction in HbA1c was comparable between insulins, regardless of subgroup. The lower risk of ≥ 1 nocturnal (00:00–05:59 h) confirmed (≤ 3.9 mmol/L [≤ 70 mg/dL]) or severe hypoglycemic event with Gla-300 versus Gla-100 was also unaffected by participant characteristics. While heterogeneity of treatment effect between diabetes duration subgroups was seen for the risk of ≥ 1 confirmed (≤ 3.9 mmol/L [≤ 70 mg/dL]) or severe hypoglycemic event at any time (24 h), treatment effect consistently favored Gla-300; no evidence of heterogeneity was observed for the other subgroups. Annualized rates of confirmed (≤ 3.9 mmol/L [≤ 70 mg/dL]) or severe hypoglycemia and body weight change were not influenced by participant characteristics; a similar pattern was observed with insulin dose. Conclusions Comparable glycemic control was observed with Gla-300 versus Gla-100, with less hypoglycemia, regardless of age, BMI, age at onset or diabetes duration.es_ES
dc.description.sponsorshipThis study was sponsored by Sanofi, Paris, France. The article processing charges were also funded by Sanofi, Paris, France. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.es_ES
dc.subjectGlycated hemoglobin Aes_ES
dc.subjectInsulin glarginees_ES
dc.subjectType 2 diabeteses_ES
dc.titleAssociation of patient profile with glycemic control and hypoglycemia with insulin glargine 300 U/mL in type 2 diabetes: A post hoc patient-level meta-analysises_ES
dc.description.noteThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.es_ES
dadun.citation.publicationNameDiabetes therapyes_ES

Files in This Item:
580.5 kB
Adobe PDF

Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.